Stock Ratings / Consumer Discretionary / PASW

TLF (35) BIRD (34) NCI (33) BRIA (49) ⌘ Pro Terminal →

Ping An Biomedical Co. Ltd. (Class A) (PASW) — RQD Stock Rating Cockpit

$5.12 +2.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.13

Ping An Biomedical Co. Ltd. (Class A) (PASW) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $16.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PASW Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PASW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Ping An Biomedical Co. Ltd. (Class A) (NASDAQ: PASW) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.12 (+2.40% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1011 tracked Consumer Discretionary issuers, PASW ranks #836 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PASW compare to TLF and BIRD in the Consumer Discretionary sector?

▼

Within the Consumer Discretionary sector (Apparel), PASW carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 2.8%, and ROIC of —. By comparison, TLF (Tandy Leather Factory Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -2.1%, cap $18.0M) and BIRD (Smartbird Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M). Among the 5-stock peer group, NCI leads on earnings multiple (153.8x) while NCI leads on capital efficiency (2.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PASW?

▼

Per PASW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001897532), Ping An Biomedical Co. Ltd. (Class A) generated $4.8M in revenue, -$1.8M in net income, and -$902.9K in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.13 (+0.24%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PASW)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY PASW SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 2.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.04-0.8% Next Q

Q2 (-2Q)

Grade E$5.00-2.4% Next Q

Q3 (-1Q)

Grade E$4.88+4.9% Next Q

Current

Grade E$5.12-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PASW Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PASW currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Discretionary with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.14) and Max Pain ($5.38) forces dealer call-delta covering toward $30.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PASW• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PASW Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

51.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE8% OF RANGE

L: $3$5.12H: $29

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PASW

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 2.8% gross margin and -5.77% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (25)

9/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like PASW

✓Established market leader in Consumer Discretionary with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PASW)

✓Walkthrough of PASW's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PASW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.50%📐 HORIZONTAL RANGE

2026-11-03O $5.00H $5.12L $5.00C $5.12VOL 62.5K

RES: $10.89SUP: $2.81SMA50: $5.14SMA200: $6.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PASW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PASW Butterfly Map → + Track PASW →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PASW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PASW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PASW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PASW)

Consumer Discretionary Rank #836 of 1011 ⚔️ TLF vs PASW Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (PASW vs. TLF, BIRD, NCI, BRIA)

Industry: Apparel (27 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Ping An Biomedical Co. Ltd. (Class A) (PASW) ranks #836 by composite RQD confidence (33/100, grade E) and #895 by equity capitalization ($16.0M). Within this direct 5-issuer industry benchmark cohort, NCI leads on earnings valuation at 153.8x trailing P/E, while NCI leads on capital efficiency and profitability with 2.6% ROIC and 36.9% gross margin. BRIA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PASW at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PASW ACTIVE Ping An Biomedical Co. Ltd. (Class A)	E	33/100	—	2.8%	—	+2.40%	$16.0M	Benchmark Subject
TLF Tandy Leather Factory Inc.	D-	35/100	—	57.0%	-2.1%	-2.65%	$18.0M	/tlf-vs-pasw →
BIRD Smartbird Inc. (Class A)	E	34/100	—	41.0%	-35.0%	-8.02%	$23.0M	/bird-vs-pasw →
NCI Neo-Concept International Group Holdings Limited (Class A)	E	33/100	153.8x	36.9%	2.6%	-2.16%	$6.4M	/nci-vs-pasw →
BRIA BrilliA Inc (Class A)	D	49/100	—	—	—	-1.43%	$42.3M	/bria-vs-pasw →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001897532

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Ping An Biomedical Co. Ltd. (Class A) (PASW) reported GAAP revenue of $4.8M , GAAP net income of -$1.8M, operating cash flow of -$902.9K, and free cash flow of -$902.9K . On the balance sheet, PASW closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$4.8M	-$1.8M	-$902.9K	-$902.9K	$9.6M	—

3. PASW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PASW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PASW compare to TLF and BIRD in the Consumer Discretionary sector?

What are the biggest fundamental strengths and SEC risk factors for PASW?

Where is PASW trading relative to its 50-day, 200-day, and 52-week technical levels?

PASW last traded at $5.12 (+2.40% on volume of 62,529 shares), positioning the stock -0.39% below its 50-day simple moving average ($5.14) and -15.93% below its 200-day simple moving average ($6.09). Across its 52-week range of $3.07 to $29.28, PASW sits at the 7.8% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.48 to $5.76).

PASW Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PASW stock right now?

Ping An Biomedical Co. Ltd. (Class A) (PASW) currently earns a Roarable Rating of E (Strong Sell — SELL) with 33/100 RQD Confidence. Stretched risk/reward at current multiples (3% profit margin) under elevated 10-year interest-rate pressure.

What is PASW's 12-month price target and RQD AI Jury consensus?

PASW's 12-month base price target is $4.54 (range $3.54 to $30.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PASW RQD Cockpit PASW 12M Forecast PASW Earnings & Move PASW Dividends & DRIP PASW Insiders & 13F PASW Whale Options PASW Profit Sankey PASW News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PASW — Ping An Biomedical Co. Ltd. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PASW carries an RQD Score of 32 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each out of 20:

Fundamental Cash Engine: 10 / 20. Per the RQD rating, ROIC is 0% and FCF yield is -5.77%. For a prospective investor, this means the business is not currently converting capital into returns and is consuming rather than generating free cash relative to its value.
Whale 13F Flow: 5 / 20. The RQD rating reflects institutional accumulation and options positioning as weak. Investors should not treat institutional support as a cushion for the stock.
Insider Conviction: 3 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is the weakest pillar, indicating little insider signaling of confidence.
Macro Regime Fit: 6 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. The stock does not offer a defensive profile relative to the market.
Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The Piotroski reading is the key red flag here, signaling weak financial quality across most tests.

Taken together, the upside case rests almost entirely on a speculative recovery, while the valuation tradeoff is unfavorable given negative margins and cash burn. A prospective investor should weigh that the rating frames the stock as a high-risk avoid rather than a value opportunity. This is educational framing, not personalized advice.

Business

Per the profile, Ping An Biomedical Co. Ltd. (Class A) is a NASDAQ-listed company in the Consumer Discretionary sector and Apparel industry. The profile lists a market capitalization of $0.0B. Not available in source data for detailed product lines, customer base, or revenue mix. Per the SEC financials, the company reported revenue of $4.8M for FY 2025.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$4.8M	$-2.1M	$-1.8M	N/A	$-0.9M	N/A	N/A

Per the market data, gross margin is 2.8%, operating margin is -43.1%, and net margin is -37.6%, with ROIC at 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, the latter indicating weak fundamental quality. Per the RQD rating, Debt/Equity is 0.5. Cash and debt figures for FY 2025 are reported as N/A in the SEC financials, so balance sheet liquidity cannot be fully assessed from the source data.

Recent Catalysts & News Wire Analysis

Reverse stock split. Multiple headlines report a 1-for-40 reverse stock split effective October 23, 2026. Stock Titan reports the consolidation will combine 40 shares into one on Oct. 23. Per the news feed, shareholders ratified the split with 30,150 votes against.
Shareholder approval of consolidation and capital increase. A TipRanks-sourced headline reports shareholders approved a major share consolidation and capital increase.
Price action. A headline reports PASW gained 2.66% to $5.01 as shares pressed toward an upper range, tagged as a CATALYST.
Watch items. Reverse splits and capital increases are commonly associated with dilution and financing pressure; the source data does not state the purpose or terms of the capital increase.
Proprietary signals. Per the Butterfly Supply-Chain Graph, there are no proprietary signals in the source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links. Sector is Consumer Discretionary and industry is Apparel, but no upstream or downstream dependencies, sector correlations, or second-order bottlenecks are available in the source data. Not available in source data for specific ripple effects.

Open Questions

What is the purpose, size, and dilution impact of the approved capital increase?
What are FY 2025 cash and debt balances, given both are reported as N/A?
Why does a 2.8% gross margin persist, and what drives the gap to -43.1% operating margin?
What explains the decline from a 52-week high of $30.56 to a low of $3.07 relative to fundamentals?
What is the company's business model and customer base, which the source data does not describe in detail?

PASW Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ping An Biomedical Co. Ltd. (Class A) (PASW) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PASW Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

Ping An Biomedical Announces 1-for-40 Reverse Stock Split

Yahoo Finance report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

Ping An Biomedical will combine 40 shares into one on Oct. 23.

Stock Titan report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Ping An Biomedical Co., Ltd. Announces 1-for-40 Reverse Stock Split Effective October 23, 2026

Quiver Quantitative report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Ping An Biomedical (PASW) Gains 2.66% to $5.01 as Shares Press Toward Upper Range - Demand Zone

https://www.dars.gov.et/ report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

With 30,150 votes against, shareholders ratify Ping An Biomedical (PASW)'s reverse split.

Stock Titan report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TipRanks • 1d ago

Ping An Biomedical Shareholders Approve Major Share Consolidation and Capital Increase

TipRanks report covering Ping An Biomedical Co. Ltd. (Class A) (PASW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 11d ago

Postmarket Movers: After-Hours Gainers and Decliners

Notable after-hours gainers included LUCD, AARD, RNG and RHI; decliners included SHFS, SDST and DECK after the US session close.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Ping An Biomedical Announces Planned Acquisition of Three Tumor Cell-Related Medical Technology Patents to Build a Core Oncology and Biotech Intellectual Property Portfolio

HONG KONG, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited (the “Letter of Inte

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PASW Bull vs. Bear Conversation Board — What's Your Call at $5.12?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PASW 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.40 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PASW (E • RQD 32/100) a Buy at $5.00?

Welcome to the PASW (Ping An Biomedical Co. Ltd. (Class A)) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Apparel. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.15 (-17.0%)

Spot @ $5.00

Pump the brakes on PASW — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PASW, but look at what you are paying: current EV/EBITDA multiples with 2.8% gross margins. Unless Ping An Biomedical Co. Ltd. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.00 (+20.0%)

Spot @ $5.00

PASW cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PASW, the market is fixating on short-term headline noise in Apparel and ignoring the balance sheet and cash flow trajectory. At $5.00 (52-wk range $3.07 - $30.56), any beat on forward guidance forces shorts and underweight funds to chase.